According to the World Health Organization (WHO), ischemic strokes account for about 90 percent of the 15 million strokes that occur worldwide each year. Hemorrhagic strokes occur when an artery in the brain bursts. Europe averages approximately 650,000 stroke deaths each year. Stroke is the leading cause of death after heart disease and cancer and WHO calls neurological disorders, which affect about 1.7 billion people, one of the greatest threats to public health.(1)(2)
The REVIVE™ SE is inserted with a microcatheter across the occlusion or beyond its distal edge, at which point it is deployed and expands into the vessel. It can be redeployed multiple times based on the severity of the clot. The device features a closed distal end to help prevent portions of the clot from moving further upstream within the vessel. The basket engages the clot for effective removal, is reconstrainable to ease retrieval, and is designed for optimal centering within the vessel lumen during deployment and retrieval.
"The REVIVE™ SE represents Codman's first product entry into ischemic stroke, due in large part to our recent acquisition of Micrus Endovascular," said Karen Prange, General Manager and Vice President, Codman Neurovascular. "This is the beginning of a long term commitment to bring forward more innovations that advance the treatment of stroke and improve patient care, outcomes and access to treatment."
Over the last several months, Codman, through its Codman Neurovascular business unit, introduced the NEUROSCOUT™ Steerable Guidewire and the XTRASOFT™ ORBIT GALAXY™ Coil globally, as well as the ENTERPRISE™ Vascular Reconstruction Device and D
|SOURCE Codman & Shurtleff, Inc.|
Copyright©2010 PR Newswire.
All rights reserved